Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 16,300 shares of the Company’s common stock at an exercise price per share of $16.28, which was the closing price on May 23, 2024, and restricted stock units to acquire a total of 8,150 shares of the Company’s common stock. The equity awards were granted pursuant to the C...